ProductsDistribution Products

ELIGARD

Therapeutic indication:

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

 

  • Composition: Leuprolide Acetate 22.5mg Leuprolide Acetate 45mg
  • Method of administration: Subcutaneous
  • Manufacturer: Tolmar Pharmaceuticals Inc., USA
ELIGARD - Product Logo
ELIGARD - Product Image

Join Our Mailing List

Sign up to receive Email updates from Kamada

Latest News

Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
Nov. 13, 2024